Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Selank, Synthetic heptapeptide
A synthetic heptapeptide analog of tuftsin studied as a non sedating anxiolytic, modulating GABA/serotonin systems and raising BDNF without dependence in studied models.

A heptapeptide built from the immune fragment tuftsin, studied as a non sedating anti anxiety agent that works on GABA and serotonin without the dependence of benzodiazepines.
Non sedating anxiolytic
BDNF support
Tuftsin lineage
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Zozulia AA, et al.
In 62 patients, Selank's anxiolytic effect was comparable to medazepam but with added antiasthenic effect and no sedation or dependence.
A Russia registered anxiolytic. Russian RCT type studies report anxiolytic efficacy comparable to benzodiazepines without sedation, dependence, or cognitive impairment; one double blind GAD trial reported larger HAM-A reduction vs placebo. Samples are small and single institution, and comparison to benzodiazepines (rather than first line SSRIs) limits Western relevance.
Well tolerated, with no dependence/withdrawal reported; long term/Western data limited.
Russia registered; not FDA approved. Category 2 (2023); nomination withdrawn Sept 2024; not yet scheduled for PCAC review. WADA: S0.
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.